nature portfolio

Corresponding author(s):	Carmen Buchrieser	
Last updated by author(s):	2021/12/08	03/11/15

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics	
For all statistical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed	AND COMMON OF THE PARTY OF THE
☐ ☐ The exact	t sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statem	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statis	stical test(s) used AND whether they are one- or two-sided non tests should be described solely by name; describe more complex techniques in the Methods section.
☐ ☐ A descrip	tion of all covariates tested
☐ ☐ A descrip	tion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full des	cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) ation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null h	hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted uses as exact values whenever suitable.
For Baye	sian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hiera	rchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Laterature (Control	s of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.
Software ar	nd code
Policy information	about <u>availability of computer code</u>
Data collection	no software was used for data collections
Data analysis	Data analysis was performed using GraphPad Prism program, version 9.3.0; Sequence analyses was udnertaken with Cutadapt software version 1.15; https://github.com/najoshi/sickle 1.33; Bowtie 2.3.4.3; Samtools suite 1.3 https://github.com/samtools/samtools; Sartools version 1.3.0; Artemis analysing tool 16.0.17; Velocity 6.5.1; Columbus 2.9.1
For manuscripts utilizing	ng custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and a procurage code denosition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

RNAseq data have been deposited at NCBI Gene Expression Omnibus (GEO) database under accession number GSE159109 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE159109) and GSE190376 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE190376), Flow cytrometry data have been deposited at https://flowrepository.org/ under accession numbers FR-FCM-Z2XL and FR-FCM-Z2XM, human genome sequence build GRCh38, http://www.mirbase.org/search.shtml (Release 22.1: October 2018)

http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS/index (Version 5.0) were used

Field-spe	ecific reporting	<u> </u>	
Maria and the second		your research. If you are not sure, read the appropriate sections before making your selection.	
Life sciences	Behavioural & so		
For a reference copy of	the document with all sections, see <u>natu</u>	re.com/documents/nr-reporting-summary-flat.pdf	
Lifo scior	nces study des	ian	
Life Sciel	ices study des	ığıı	
All studies must dis Sample size	isclose on these points even when the disclosure is negative. Not applicable		
Data exclusions	No data have been excluded		
Replication	Experiments were replicated as stated in the methods section and figure legends but at least 3 times		
Randomization	There was no randomization		
Blinding	No blinding was performed.		
		A september on wheel or measurements were taken from distinct and play or substitute that are the substi-	
Danastis	a for openific	sataviala avatavas avad vastlanda	
NAME OF TAXABLE PARTY.		naterials, systems and methods	
		of materials, experimental systems and methods used in many studies. Here, indicate whether each material, are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & ex	perimental systems	Methods	
n/a Involved in the study		n/a Involved in the study	
Antibodies		ChIP-seq	
Eukaryotic		Flow cytometry	
	ogy and archaeology	MRI-based neuroimaging	
	d other organisms earch participants		
Clinical dat			
	esearch of concern		
Antibodies		at the state of th	
Antibodies used		Signaling 2897 1:50 https://media.cellsignal.com/coa/2897/2897-coa.pdf	
		gnaling 2792 1:50 https://media.cellsignal.com/coa/2792/2792-coa.pdf ing 3743 1:1000 https://media.cellsignal.com/coa/3743/3743-coa.pdf	
		ling 4504 1:1000 https://media.cellsignal.com/coa/4504/4504-coa.pdf 1:1000 https://media.cellsignal.com/coa/4727/4727-coa.pdf	
	P-TBK1/NAK (Ser172) (DS	52C2) Cell Signaling 5483 1:1000 https://media.cellsignal.com/coa/5483/5483-coa.pdf	
	P-IRF3 (Ser396) (4D4G) C ser396-4d4g-rabbit-mab	tell Signaling 4947 1:1000 https://www.cellsignal.com/products/primary-antibodies/phospho-irf-3- /4947	
	P-IRF7 (Ser471/472) Cell	Signaling 5184 1:1000 https://www.cellsignal.com/products/primary-antibodies/phospho-irf-7-ser471-472-	
	antibody/5184 P-IkBa (Ser32/36) (5A5) (Cell Signaling 9246 1:1000 https://media.cellsignal.com/coa/9246/9246-coa.pdf	
		BH1) Cell Signaling 3033 1:1000 https://media.cellsignal.com/coa/3033/3033-coa.pdf ed Cell Signaling 7074 1:5000 https://media.cellsignal.com/coa/7074/7074-coa.pdf	
	Anti-mouse IgG, HRP-link	ed Cell Signaling 7076 1:5000 https://media.cellsignal.com/coa/7076/7076-coa.pdf	
	RhoGDIa (A20) Santa Cru Biotin Monoclonal Antibo	z Biotechnology sc-360 1:2000 https://www.citeab.com/antibodies/826384-sc-360-rho-gdi-antibody-a-20 ody (Z021) Invitrogen 033700 1:2000 https://www.thermofisher.com/antibody/product/Biotin-Antibody-	
	clone-Z021-Monoclonal/		
Validation		of our antibodies but we relied on the validtaion done by the manufacturer. Please find here each technical	
		acturer with the description of the validation com/coa/2897/2897-coa.pdf	
	https://media.cellsignal.c	com/coa/2792/2792-coa.pdf	
		com/coa/3743/3743-coa.pdf com/coa/4504/4504-coa.pdf	
		com/coa/4727/4727-coa.pdf	

https://media.cellsignal.com/coa/5483/5483-coa.pdf

https://www.cellsignal.com/products/primary-antibodies/phospho-irf-3-ser 396-4d4g-rabbit-mab/4947

https://www.cellsignal.com/products/primary-antibodies/phospho-irf-7-ser471-472-antibody/5184

https://media.cellsignal.com/coa/9246/9246-coa.pdf

https://media.cellsignal.com/coa/3033/3033-coa.pdf

https://media.cellsignal.com/coa/7074/7074-coa.pdf

https://media.cellsignal.com/coa/7076/7076-coa.pdf

https://www.citeab.com/antibodies/826384-sc-360-rho-gdi-antibody-a-20 https://www.thermofisher.com/antibody/product/Biotin-Antibody-clone-Z021-Monoclonal/03-3700

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s) Cell lines used were THP-1 purchased from ATCC and U2OS-Sec61® cells published in Proc Natl Acad Sci U S A. 2016 Feb

16;113(7):1901-6. doi: 10.1073/pnas.1522067113

Authentication Standard cell lines were used, no particular authentification process was conducted

Mycoplasma contamination All cell lines were tested for Mycoplasma contamination and tested negative

Commonly misidentified lines (See ICLAC register)

We did not use any commonly misidentifed cell lines in this study

Flow Cytometry

Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

The samples were prepared as described in the M&M section. L. pneumophila strains were grown in BYE until post-exponential phase (OD4.2). Bacterial cells were harvested by centrifugation at 5.000xg, 4°C for 15 min and the pellet was frozen at -80°C for further use. The supernatant was twice passed through a 0.2µm PES membrane Stericup® Quick Release (Millipore) and re-centrifuged for 15min at 15.000xg, 4°C. The supernatant was treated with RNaseA/T1 (Thermo Scientific) at a final concentration of 2µg/ml RNaseA for 1h at 37°C followed by centrifugation at 150.000xg for 2h at 4°C to pellet the Lp-EVs. The Lp-EV-pellet was washed, re-centrifuged and resuspended in PBS. For incubation experiments with U2OS or hMDM for FISH, the purified Lp-EVs were labelled with Vybrant DiD-dye (Thermo Scientific), 30min at 37°C and subsequently cleaned-up using Exosome Spin Columns (MW3000, Thermo Scientific) for removal of unincorporated dye. Human cells were incubated with Lp-EVs at an MOI of 10 (according to flow cytometry dye-labelled events).

Instrument

MACSQuant flow cytometer and ZetaView® QUATT

Software

The data were analysed with FlowJo software

Cell population abundance

We did not sort any populations thus no post sort fractions details can be given

Gating strategy

Figure S1B shows representative flow cytometry results showing labelling and gating strategies to evaluate the SSC resolution of purified Lp-EVs to analyse size-related parameters. a) Column A shows a representative control experiment using DiD dye in PBS alone, to be able to distinguish Lp-EVs from the background noise. b) Colum B shows Lp-EVs labelled with DiD dye (PE-Vio770-H channel. c) Optimization of the cytometer settings for discriminating the 4 individual peaks of the green fluorescent Megamix-Plus SSC beads (GFP-FITC-H channel). d) Adjustments were used to characterize stained standardization beads and Lp-EVs, to determine the approximate diameter represented as a side scatter SSC-H x count histogram

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.